Company intelligence / Profile preview

NestedwithStyle

Cambridge, Massachusetts, USAnestedwithstyle.com ↗

Ownership: Private
Development stage: Commercial

Overview

Nested Therapeutics’ lead candidate NST-628 is a non-degrading, fully brain penetrant pan-RAF/MEK molecular glue targeting multiple critical components of the RAS/MAPK pathway. It has shown superiority over single agents and combinations in preclinical models of RAS/MAPK-driven cancers. NST-628 is currently being evaluated in a global two-part Phase 1 study for patients with MAPK-driven solid tumors. A second program targets a cryptic pocket on a transcriptional regulator within the p53 pathway; this program has identified a lead compound with selective target binding

Therapeutic areas: Oncology
Modalities: Small moleculeMolecular glue therapy
Industry: Biotech

Beyond the preview

Go deeper on NestedwithStyle.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NestedwithStyle.

Explore the full profile